drugset / Trial / NCT02299999

SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

NCT02299999

Phase 2 Active not recruiting 1460 enrolled UNICANCER AstraZeneca · collabFondation ARC · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

Open label multicentric phase II randomized trial, using high throughput genome analysis as a therapeutic decision tool, which aims at comparing a targeted treatment administered according to the identified molecular anomalies of the tumor with maintenance chemotherapy (targeted substudy 1) as well as immunotherapy with maintenance chemotherapy in patients without actionable genomic alterations or non eligible to substudy 1 (immune substudy 2).

Timeline

Start
2014-04-07
Primary completion
2022-12
Completion
2025-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Bicalutamide Other / unclassified 150 mg Oral
Subject Capivasertib Small molecule 480 mg Oral
Subject Durvalumab Monoclonal antibody 10 mg/kg Intravenous
Subject Fexagratinib Small molecule 80 mg Oral
Subject Olaparib Small molecule 300 mg Oral
Subject SAPITINIB Small molecule 40 mg Oral
Subject Selumetinib Small molecule 75 mg Oral
Subject Vandetanib Small molecule 300 mg Oral
Subject Vistusertib Small molecule 50 mg Oral
Comparator Bevacizumab Monoclonal antibody
Comparator Capecitabine Small molecule
Comparator Carboplatin Small molecule
Comparator Cisplatin Other / unclassified
Comparator Cyclophosphamide Other / unclassified
Comparator Docetaxel Small molecule
Comparator Doxorubicin Other / unclassified
Comparator Epirubicin Small molecule
Comparator Eribulin Small molecule
Comparator Gemcitabine Small molecule
Comparator Methotrexate Small molecule
Comparator Mitomycin C Other / unclassified
Comparator Paclitaxel Small molecule
Comparator Vinblastine Small molecule
Comparator Vincristine Small molecule
Comparator Vinorelbine Small molecule
Comparator fluorouracil Small molecule

Indications